<![CDATA[FDA Issues Complete Response Letter for Orviglance in Liver Imaging]]>
rejectedOrviglanceNegative
AI Analysis
Summary
The FDA issued a Complete Response Letter declining approval of Orviglance for MRI liver imaging in patients with severe kidney impairment, requesting additional clinical data from the developer.
Outcome Details
FDA issued Complete Response Letter declining approval for Orviglance; additional clinical data requested
Importance:8/10
Sentiment:
-0.80
FDACRLLiver ImagingRegulatory Setback
Read the original article
Published by Cancer Network on July 7, 2026 4:00 PM